Differences in Treatment Response in Bronchial Epithelial Cells from Idiopathic Pulmonary Fibrosis (IPF) Patients: A First Step towards Personalized Medicine?
Idiopathic pulmonary fibrosis (IPF) has a detrimental prognosis despite antifibrotic therapies to which individual responses vary. IPF pathology is associated with oxidative stress, inflammation and increased activation of SRC family kinases (SFK). This pilot study evaluates individual responses to...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Antioxidants |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3921/12/2/443 |
| _version_ | 1797622689719910400 |
|---|---|
| author | C. Veith M. A. Schneider L. Maas A. van der Vliet F. J. van Schooten M. Kreuter M. Meister A. W. Boots N. Kahn |
| author_facet | C. Veith M. A. Schneider L. Maas A. van der Vliet F. J. van Schooten M. Kreuter M. Meister A. W. Boots N. Kahn |
| author_sort | C. Veith |
| collection | DOAJ |
| description | Idiopathic pulmonary fibrosis (IPF) has a detrimental prognosis despite antifibrotic therapies to which individual responses vary. IPF pathology is associated with oxidative stress, inflammation and increased activation of SRC family kinases (SFK). This pilot study evaluates individual responses to pirfenidone, nintedanib and SFK inhibitor saracatinib, markers of redox homeostasis, fibrosis and inflammation, in IPF-derived human bronchial epithelial (HBE) cells. Differentiated HBE cells from patients with and without IPF were analyzed for potential alterations in redox and profibrotic genes and pro-inflammatory cytokine secretion. Additionally, the effects of pirfenidone, nintedanib and saracatinib on these markers were determined. HBE cells were differentiated into a bronchial epithelium containing ciliated epithelial, basal, goblet and club cells. NOX4 expression was increased in IPF-derived HBE cells but differed on an individual level. In patients with higher NOX4 expression, pirfenidone induced antioxidant gene expression. All drugs significantly decreased NOX4 expression. IL-6 (<i>p</i> = 0.09) and IL-8 secretion (<i>p</i> = 0.014) were increased in IPF-derived HBE cells and significantly reduced by saracatinib. Finally, saracatinib significantly decreased TGF-β gene expression. Our results indicate that treatment responsiveness varies between IPF patients in relation to their oxidative and inflammatory status. Interestingly, saracatinib tends to be more effective in IPF than standard antifibrotic drugs. |
| first_indexed | 2024-03-11T09:13:50Z |
| format | Article |
| id | doaj.art-32f3e91e57d44410b5101620a3396c51 |
| institution | Directory Open Access Journal |
| issn | 2076-3921 |
| language | English |
| last_indexed | 2024-03-11T09:13:50Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antioxidants |
| spelling | doaj.art-32f3e91e57d44410b5101620a3396c512023-11-16T18:48:16ZengMDPI AGAntioxidants2076-39212023-02-0112244310.3390/antiox12020443Differences in Treatment Response in Bronchial Epithelial Cells from Idiopathic Pulmonary Fibrosis (IPF) Patients: A First Step towards Personalized Medicine?C. Veith0M. A. Schneider1L. Maas2A. van der Vliet3F. J. van Schooten4M. Kreuter5M. Meister6A. W. Boots7N. Kahn8Department of Pharmacology and Toxicology, NUTRIM School of Nutrition, Translational Research and Metabolism, Faculty Health, Medicine and Life Sciences, University of Maastricht, P.O. Box 616, 6200 MD Maastricht, The NetherlandsTranslational Lung Research Unit, Thoraxklinik, Heidelberg University Hospital, 69126 Heidelberg, GermanyDepartment of Pharmacology and Toxicology, NUTRIM School of Nutrition, Translational Research and Metabolism, Faculty Health, Medicine and Life Sciences, University of Maastricht, P.O. Box 616, 6200 MD Maastricht, The NetherlandsDepartment of Pathology & Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USADepartment of Pharmacology and Toxicology, NUTRIM School of Nutrition, Translational Research and Metabolism, Faculty Health, Medicine and Life Sciences, University of Maastricht, P.O. Box 616, 6200 MD Maastricht, The NetherlandsTranslational Lung Research Center Heidelberg, 69120 Heidelberg, GermanyTranslational Lung Research Unit, Thoraxklinik, Heidelberg University Hospital, 69126 Heidelberg, GermanyDepartment of Pharmacology and Toxicology, NUTRIM School of Nutrition, Translational Research and Metabolism, Faculty Health, Medicine and Life Sciences, University of Maastricht, P.O. Box 616, 6200 MD Maastricht, The NetherlandsTranslational Lung Research Unit, Thoraxklinik, Heidelberg University Hospital, 69126 Heidelberg, GermanyIdiopathic pulmonary fibrosis (IPF) has a detrimental prognosis despite antifibrotic therapies to which individual responses vary. IPF pathology is associated with oxidative stress, inflammation and increased activation of SRC family kinases (SFK). This pilot study evaluates individual responses to pirfenidone, nintedanib and SFK inhibitor saracatinib, markers of redox homeostasis, fibrosis and inflammation, in IPF-derived human bronchial epithelial (HBE) cells. Differentiated HBE cells from patients with and without IPF were analyzed for potential alterations in redox and profibrotic genes and pro-inflammatory cytokine secretion. Additionally, the effects of pirfenidone, nintedanib and saracatinib on these markers were determined. HBE cells were differentiated into a bronchial epithelium containing ciliated epithelial, basal, goblet and club cells. NOX4 expression was increased in IPF-derived HBE cells but differed on an individual level. In patients with higher NOX4 expression, pirfenidone induced antioxidant gene expression. All drugs significantly decreased NOX4 expression. IL-6 (<i>p</i> = 0.09) and IL-8 secretion (<i>p</i> = 0.014) were increased in IPF-derived HBE cells and significantly reduced by saracatinib. Finally, saracatinib significantly decreased TGF-β gene expression. Our results indicate that treatment responsiveness varies between IPF patients in relation to their oxidative and inflammatory status. Interestingly, saracatinib tends to be more effective in IPF than standard antifibrotic drugs.https://www.mdpi.com/2076-3921/12/2/443IPFprimary bronchial epithelial cellsnintedanibpirfenidonesaracatinibpersonalized medicine |
| spellingShingle | C. Veith M. A. Schneider L. Maas A. van der Vliet F. J. van Schooten M. Kreuter M. Meister A. W. Boots N. Kahn Differences in Treatment Response in Bronchial Epithelial Cells from Idiopathic Pulmonary Fibrosis (IPF) Patients: A First Step towards Personalized Medicine? Antioxidants IPF primary bronchial epithelial cells nintedanib pirfenidone saracatinib personalized medicine |
| title | Differences in Treatment Response in Bronchial Epithelial Cells from Idiopathic Pulmonary Fibrosis (IPF) Patients: A First Step towards Personalized Medicine? |
| title_full | Differences in Treatment Response in Bronchial Epithelial Cells from Idiopathic Pulmonary Fibrosis (IPF) Patients: A First Step towards Personalized Medicine? |
| title_fullStr | Differences in Treatment Response in Bronchial Epithelial Cells from Idiopathic Pulmonary Fibrosis (IPF) Patients: A First Step towards Personalized Medicine? |
| title_full_unstemmed | Differences in Treatment Response in Bronchial Epithelial Cells from Idiopathic Pulmonary Fibrosis (IPF) Patients: A First Step towards Personalized Medicine? |
| title_short | Differences in Treatment Response in Bronchial Epithelial Cells from Idiopathic Pulmonary Fibrosis (IPF) Patients: A First Step towards Personalized Medicine? |
| title_sort | differences in treatment response in bronchial epithelial cells from idiopathic pulmonary fibrosis ipf patients a first step towards personalized medicine |
| topic | IPF primary bronchial epithelial cells nintedanib pirfenidone saracatinib personalized medicine |
| url | https://www.mdpi.com/2076-3921/12/2/443 |
| work_keys_str_mv | AT cveith differencesintreatmentresponseinbronchialepithelialcellsfromidiopathicpulmonaryfibrosisipfpatientsafirststeptowardspersonalizedmedicine AT maschneider differencesintreatmentresponseinbronchialepithelialcellsfromidiopathicpulmonaryfibrosisipfpatientsafirststeptowardspersonalizedmedicine AT lmaas differencesintreatmentresponseinbronchialepithelialcellsfromidiopathicpulmonaryfibrosisipfpatientsafirststeptowardspersonalizedmedicine AT avandervliet differencesintreatmentresponseinbronchialepithelialcellsfromidiopathicpulmonaryfibrosisipfpatientsafirststeptowardspersonalizedmedicine AT fjvanschooten differencesintreatmentresponseinbronchialepithelialcellsfromidiopathicpulmonaryfibrosisipfpatientsafirststeptowardspersonalizedmedicine AT mkreuter differencesintreatmentresponseinbronchialepithelialcellsfromidiopathicpulmonaryfibrosisipfpatientsafirststeptowardspersonalizedmedicine AT mmeister differencesintreatmentresponseinbronchialepithelialcellsfromidiopathicpulmonaryfibrosisipfpatientsafirststeptowardspersonalizedmedicine AT awboots differencesintreatmentresponseinbronchialepithelialcellsfromidiopathicpulmonaryfibrosisipfpatientsafirststeptowardspersonalizedmedicine AT nkahn differencesintreatmentresponseinbronchialepithelialcellsfromidiopathicpulmonaryfibrosisipfpatientsafirststeptowardspersonalizedmedicine |